Topic · 6 reports

Antitrust

RegulationWatch reporting on antitrust matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.

  1. Antitrust

    Forty-five states seek approval of generic price-fixing settlements with Ascend, Mayne and Citron

    A 45-state coalition asked the court to approve settlements with three more generic manufacturers in the long-running price-fixing litigation. The monetary terms total $1.05 million; the larger cases against Teva, Sandoz and others continue.

  2. Antitrust

    States seek approval of Sandoz settlement worth approximately $469 million

    State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.

  3. Antitrust

    Caremark wins partial dismissal while Rxeed interference claim survives

    A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.

  4. Antitrust

    Florida sues Prime Therapeutics and Express Scripts over alleged pharmacy price-fixing

    Florida Attorney General James Uthmeier has sued Prime Therapeutics LLC and Express Scripts, Inc., alleging the two pharmacy benefit managers entered a horizontal price-fixing agreement that cut reimbursements to Florida pharmacies. The state seeks injunctive relief, civil penalties, disgorgement and damages.

  5. Antitrust

    Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.

    The deal carries no admission. The company had already reserved for it.

  6. Antitrust

    Sandoz agrees $450 million settlement with 43 states over generic drug pricing

    Sandoz has agreed to pay about $450 million to resolve antitrust claims brought by 43 US states and territories over alleged price-fixing and market allocation in the generic drug market. The company said the deal contains no admission of wrongdoing and resolves all remaining US government claims against it from the long-running investigation.